Verdence Capital Advisors LLC Has $1.49 Million Position in Sanofi (NASDAQ:SNY)

Verdence Capital Advisors LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,909 shares of the company’s stock after purchasing an additional 386 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Sanofi were worth $1,491,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its stake in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares during the last quarter. Natixis Advisors LLC increased its stake in shares of Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after acquiring an additional 114,133 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the last quarter. DAVENPORT & Co LLC increased its stake in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Trading Up 2.5 %

Shares of NASDAQ:SNY opened at $59.15 on Thursday. The stock has a market capitalization of $150.11 billion, a PE ratio of 23.76, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 1 year low of $45.22 and a 1 year high of $59.19. The firm has a fifty day moving average price of $52.22 and a 200 day moving average price of $52.68. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.